The Angeles Clinic and Research Institute Releases Interim Data From Study Evaluating Investigational Anti-PD-1 Antibody in Patients With Advanced Melanoma
6/5/2013 10:03:02 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
LOS ANGELES--(BUSINESS WIRE)--The Angeles Clinic and Research Institute has released preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), an investigational antibody therapy currently being developed by Merck that targets programmed cell death-1 protein (PD-1) in patients with advanced (inoperable and metastatic) melanoma. The study (Abstract #9009) was presented at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting convening in Chicago this week and published concurrently online in the New England Journal of Medicine (N Engl J Med 2013. DOI: 10.1056/NEJMoa1305133).
Help employers find you! Check out all the jobs and post your resume.
comments powered by